Phase II Study Incorporating Pegylated Interferon in the Treatment for Children with High-Risk Melanoma

Trial Profile

Phase II Study Incorporating Pegylated Interferon in the Treatment for Children with High-Risk Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Temozolomide (Primary) ; Interferon alpha-2b; Peginterferon
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 24 Apr 2014 Planned End Date changed from 1 Dec 2016 to 1 Sep 2018.
    • 15 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top